OXB — Oxford BioMedica Share Price
- £357.11m
- £368.68m
- £89.54m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.83 | ||
Price to Tang. Book | 8.3 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 3.99 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -88.53% | ||
Return on Equity | -113.03% | ||
Operating Margin | -205.69% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | £m | 64.06 | 87.73 | 142.8 | 139.99 | 89.54 | 129.35 | 165.49 | 6.04% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
Directors
- Roch Doliveux NEC (65)
- Stuart Henderson VCH
- Stuart Paynter CFO
- Nick Page COO
- Helen Stephenson-Ellis CHO
- James Miskin CTO
- Kyriacos Mitrophanous CSO
- Natalie Walter GCN
- Jason Slingsby OTH
- Robert Ghenchev NED
- Michael Hayden NED (69)
- Dame Kay Davies NID
- Catherine Moukheibir NID (62)
- Heather Preston NID (55)
- Siyamak Rasty NID
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 20th, 1996
- Public Since
- November 15th, 1996
- No. of Employees
- 714
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 105,341,569
- Address
- Windrush Court, Transport Way, OXFORD, OX4 6LT
- Web
- https://www.oxb.com/
- Phone
- +44 1865783000
- Contact
- Sophia Bolhassan
- Auditors
- KPMG LLP
Latest News for OXB
Upcoming Events for OXB
Half Year 2024 Oxford Biomedica PLC Earnings Release
Similar to OXB
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 22:59 UTC, shares in Oxford BioMedica are trading at 339.00p. This share price information is delayed by 15 minutes.
Shares in Oxford BioMedica last closed at 339.00p and the price had moved by +26.02% over the past 365 days. In terms of relative price strength the Oxford BioMedica share price has outperformed the FTSE All Share Index by +16.77% over the past year.
The overall consensus recommendation for Oxford BioMedica is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOxford BioMedica does not currently pay a dividend.
Oxford BioMedica does not currently pay a dividend.
Oxford BioMedica does not currently pay a dividend.
To buy shares in Oxford BioMedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 339.00p, shares in Oxford BioMedica had a market capitalisation of £357.11m.
Here are the trading details for Oxford BioMedica:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: OXB
Based on an overall assessment of its quality, value and momentum Oxford BioMedica is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oxford BioMedica is 460.13p. That is 35.73% above the last closing price of 339.00p.
Analysts covering Oxford BioMedica currently have a consensus Earnings Per Share (EPS) forecast of -£0.37 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oxford BioMedica. Over the past six months, its share price has outperformed the FTSE All Share Index by +67.15%.
As of the last closing price of 339.00p, shares in Oxford BioMedica were trading +30.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oxford BioMedica PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 339.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oxford BioMedica's management team is headed by:
- Roch Doliveux - NEC
- Stuart Henderson - VCH
- Stuart Paynter - CFO
- Nick Page - COO
- Helen Stephenson-Ellis - CHO
- James Miskin - CTO
- Kyriacos Mitrophanous - CSO
- Natalie Walter - GCN
- Jason Slingsby - OTH
- Robert Ghenchev - NED
- Michael Hayden - NED
- Dame Kay Davies - NID
- Catherine Moukheibir - NID
- Heather Preston - NID
- Siyamak Rasty - NID